MDRX - Allscripts Healthcare Solutions Inc Stock Price, Fair Value and News

7.51USD-0.19 (-2.47%)Market Closed

Market Summary

USD7.51-0.19

Market Closed

-2.47%

MDRX Alerts

1 major insider buys recently.

MDRX Stock Price

View Fullscreen

MDRX RSI Chart

MDRX Valuation

Market Cap

934.2M

Price/Earnings (Trailing)

15.41

Price/Sales (Trailing)

1.12

EV/EBITDA

2.14

Price/Free Cashflow

6.04

MDRX Price/Sales (Trailing)

MDRX Profitability

Free Cashflow Yield

16.56%

MDRX Fundamentals

MDRX Revenue

MDRX Earnings

Breaking Down MDRX Revenue

Last 7 days

-7.8%

Last 30 days

-10.6%

Last 90 days

-19.9%

Trailing 12 Months

-38.9%

How does MDRX drawdown profile look like?

MDRX Financial Health

MDRX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	820.2M	829.9M	837.2M	0
2021	1.3B	1.0B	805.9M	811.2M
2020	1.6B	1.6B	1.5B	1.5B
2019	1.7B	1.7B	1.7B	1.6B
2018	1.6B	1.7B	1.7B	1.7B
2017	1.5B	1.5B	1.5B	1.5B
2016	1.4B	1.4B	1.5B	1.5B
2015	1.4B	1.4B	1.4B	1.4B
2014	1.4B	1.4B	1.4B	1.4B
2013	1.4B	1.4B	1.4B	1.4B
2012	1.5B	1.5B	1.5B	1.4B
2011	1.1B	1.3B	1.4B	1.4B
2010	661.9M	704.5M	922.2M	1.0B
2009	0	534.0M	576.6M	619.3M
2008	0	383.8M	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Allscripts Healthcare Solutions Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	langan thomas	acquired	-	-	10,304	president & cco
Apr 01, 2024	hammond lisa	sold (taxes)	-1,505	7.8	-193	svp & chief hr officer
Apr 01, 2024	langan thomas	sold (taxes)	-44,530	7.8	-5,709	president & cco
Mar 02, 2024	vakharia tejal	sold (taxes)	-78,978	6.13	-12,884	svp general counsel
Mar 02, 2024	vakharia tejal	acquired	-	-	32,982	svp general counsel
Mar 01, 2024	stonehill capital management llc	bought	23,987,200	6.00	3,997,880	-
Feb 29, 2024	stonehill capital management llc	bought	3,197,250	6.09	525,000	-
Feb 28, 2024	stonehill capital management llc	bought	38,817,000	6.81	5,700,000	-

Which funds bought or sold MDRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-399	-	-%
Apr 11, 2024	City State Bank	sold off	-100	-2,000	-	-%
Apr 10, 2024	ATWOOD & PALMER INC	sold off	-100	-20,194	-	-%
Apr 05, 2024	CWM, LLC	added	1,440	5,000	6,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	37.92	444	3,165	-%
Apr 03, 2024	Versant Capital Management, Inc	reduced	-56.99	-668	308	-%
Mar 22, 2024	Livelsberger Financial Advisory	new	-	1,941	1,941	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-74.7	-336,100	85,063	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.67	-36,578,900	149,754,000	-%
Mar 05, 2024	Fisher Asset Management, LLC	reduced	-21.00	-13,908,900	23,752,200	0.01%

Are Funds Buying or Selling MDRX?

Are funds buying MDRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MDRX

No. of Funds

MDRX Alerts

1 major insider buys recently.

Unveiling Allscripts Healthcare Solutions Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	blackrock inc.	0.0%	7,625	SC 13G/A
Mar 12, 2024	kent lake capital llc	5.54%	6e+06	SC 13G
Mar 11, 2024	vanguard group inc	3.38%	3,697,374	SC 13G/A
Mar 08, 2024	newtyn management, llc	9.6%	10,500,000	SC 13G
Mar 07, 2024	blackrock inc.	9.5%	10,412,077	SC 13G/A
Mar 04, 2024	stonehill capital management llc	19.5%	21,141,983	SC 13G
Feb 13, 2024	vanguard group inc	13.07%	14,275,875	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	8.2%	8,977,642	SC 13G/A
Feb 08, 2024	wellington management group llp	5.31%	5,806,297	SC 13G
Jan 22, 2024	blackrock inc.	17.3%	18,880,525	SC 13G/A

Recent SEC filings of Allscripts Healthcare Solutions Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	8-K	Current Report
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	8-K	Current Report
Mar 15, 2024	3/A	Insider Trading
Mar 15, 2024	4/A	Insider Trading
Mar 13, 2024	8-K	Current Report
Mar 12, 2024	SC 13G	Major Ownership Report
Mar 11, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Allscripts Healthcare Solutions Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	410.7B	371.6B	-9.23%	-12.95%	18.35	1.11	14.64%	11.24%
CI	102.0B	195.3B	-0.90%	34.65%	18.99	0.52	8.17%	-20.79%
CVS	86.8B	357.8B	-10.90%	-7.68%	10.39	0.24	10.95%	93.52%
HCA	85.3B	65.0B	0.18%	18.00%	16.28	1.31	7.86%	-7.11%
CNC	38.9B	154.0B	-3.67%	6.80%	14.39	0.25	6.54%	124.79%
UHS	11.5B	14.3B	-4.30%	22.39%	16.07	0.81	6.59%	6.24%
DVA	11.4B	12.1B	-4.93%	54.73%	16.48	0.94	4.57%	23.40%
MID-CAP
CHE	9.3B	2.3B	-4.81%	9.59%	34.17	4.11	6.06%	9.17%
ACHC	6.7B	2.9B	-6.00%	-3.46%	-311.45	2.3	12.20%	-107.93%
AMEH	2.2B	1.4B	-1.50%	0.56%	35.86	1.57	21.19%	34.42%
AMN	2.2B	3.8B	-2.74%	-34.13%	10.27	0.57	-27.73%	-52.50%
SMALL-CAP
ADUS	1.6B	1.1B	0.06%	-12.91%	25.13	1.48	11.31%	35.83%
BKD	1.2B	3.0B	5.33%	55.67%	-6.33	0.4	6.74%	20.73%
BEAT	48.4M	-	-23.65%	-14.81%	-3.31	-	-	-12.94%
AMS	18.2M	21.3M	11.67%	2.14%	34.08	0.85	8.00%	-62.25%

Allscripts Healthcare Solutions Inc News

Latest updates

Allscripts Healthcare Solutions Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Revenue	0.7%	152	151	143	392	145	141	134	386	366	369	381	414	408	411	399	442	432	441	434	436	368
Cost Of Revenue	-4.1%	68.00	71.00	69.00	665	75.00	73.00	71.00	225	230	232	249	262	260	252	249	254	254	268	249	260	206
Gross Profit	5.0%	83.00	79.00	73.00	419	70.00	68.00	63.00	161	135	138	132	153	149	159	150	188	178	174	185	176	162
S&GA Expenses	-45.7%	33.00	60.00	41.00	226	27.00	28.00	32.00	94.00	93.00	110	93.00	108	96.00	100	96.00	100	108	123	120	123	94.00
R&D Expenses	4.1%	24.00	23.00	23.00	131	21.00	21.00	21.00	54.00	46.00	46.00	59.00	60.00	61.00	62.00	62.00	66.00	63.00	74.00	65.00	68.00	46.00
EBITDA Margin	-3.2%	0.36*	0.37*	0.42*	0.43*	0.12*	0.09*	0.06*	0.05*	0.06*	0.06*	-0.03*	-0.02*	-	-	-	-	-	-	-	-	-
Interest Expenses	-34.0%	1.00	2.00	2.00	3.00	4.00	3.00	3.00	6.00	7.00	10.00	11.00	12.00	11.00	10.00	10.00	14.00	13.00	12.00	12.00	12.00	9.00
Income Taxes	261.7%	14.00	-8.58	-14.42	15.00	7.00	4.00	1.00	-10.05	-4.12	2.00	-4.53	-29.74	-5.64	-5.26	-2.69	-5.45	-1.64	7.00	0.00	-9.97	2.00
Earnings Before Taxes	566.3%	25.00	-5.32	4.00	99.00	27.00	30.00	5.00	-74.75	-18.07	-19.57	-36.92	-63.60	-25.39	-168	-23.96	-40.04	-13.78	92.00	-24.86	-32.58	-12.03
EBT Margin	-3.0%	0.15*	0.15*	0.20*	0.20*	-0.01*	-0.06*	-0.09*	-0.10*	-0.09*	-0.09*	-0.18*	-0.17*	-	-	-	-	-	-	-	-	-
Net Income	122.7%	15.00	-64.03	23.00	87.00	16.00	22.00	9.00	728	1.00	-7.60	-20.35	-18.97	-5.72	-149	-7.98	386	-23.85	74.00	-28.51	15.00	-17.46
Net Income Margin	-3.5%	0.07*	0.08*	0.18*	0.17*	0.96*	0.74*	0.58*	0.47*	-0.03*	-0.03*	-0.12*	-0.11*	-	-	-	-	-	-	-	-	-
Free Cashflow	1048.9%	28.00	-2.94	69.00	61.00	55.00	-200	4.00	-187	50.00	21.00	-6.48	9.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Assets	-1.4%	1,691	1,714	2,430	2,425	2,484	2,540	2,871	2,918	3,146	3,189	3,253	3,206	3,230	3,235	3,242	3,181	4,518	4,354	4,370	4,230	3,883
Current Assets	-2.2%	811	829	1,541	761	805	841	1,135	1,153	949	870	907	841	774	804	834	859	844	856	911	857	668
Cash Equivalents	-1.5%	493	500	83.00	133	142	160	454	531	219	199	204	130	129	139	137	174	91.00	114	112	131	104
Net PPE	-21.8%	12.00	15.00	9.00	10.00	54.00	59.00	67.00	72.00	70.00	76.00	82.00	88.00	97.00	106	116	122	160	161	165	135	165
Goodwill	0.0%	524	524	520	507	974	975	975	975	1,287	1,361	1,361	974	1,387	1,382	1,374	986	2,208	100	2,051	1,293	61.00
Liabilities	-0.8%	514	518	1,077	1,017	1,066	1,147	1,193	1,251	1,938	1,946	2,011	1,921	1,949	1,919	1,786	1,601	2,933	2,756	2,816	2,639	2,316
Current Liabilities	-1.3%	253	256	647	547	567	596	880	935	745	1,111	1,158	1,211	1,177	880	800	798	894	907	889	890	684
Long Term Debt	0.2%	200	200	377	350	373	421	169	168	1,026	662	680	551	555	823	766	648	1,002	983	1,064	907	747
LT Debt, Current	-	-	-	-	-	-	-	-	-	48.00	375	371	364	359	22.00	21.00	20.00	20.00	20.00	20.00	28.00	25.00
LT Debt, Non Current	0.2%	200	200	377	350	373	421	169	168	1,026	662	680	551	555	823	766	648	1,002	983	1,064	907	747
Shareholder's Equity	-1.6%	1,177	1,196	1,353	1,408	1,419	1,393	1,679	1,666	1,208	1,243	1,242	1,285	1,281	1,316	1,456	1,580	1,117	1,142	1,110	1,160	1,105
Retained Earnings	2.0%	753	739	803	13.00	680	664	642	633	-94.71	-95.25	-87.64	-49.34	-30.37	-24.64	125	133	-251	-228	-319	-338	-354
Additional Paid-In Capital	0.0%	1,924	1,924	1,922	1,962	1,952	1,904	1,907	1,903	1,929	1,921	1,915	1,907	1,876	1,868	1,858	1,881	1,765	1,767	1,771	1,781	1,782
Shares Outstanding	-1.4%	109	111	115	116	123	125	141	140	158	163	162	162	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29.00	29.00	29.00	38.00	39.00	41.00
Float	-	-	-	-	-	-	2,252	-	-	-	1,079	-	-	-	1,894	-	-	-	2,056	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Cashflow From Operations	1821.2%	28,141	-1,635	69,261	65,045	55,889	-200,937	4,575	-178,620	52,967	22,646	-3,708	12,310	35,854	-7,726	5,816	-13,663	15,014	8,232	58,308	106,232	63,824
Share Based Compensation	-49.5%	4,553	9,024	6,324	26,365	3,982	1,981	2,841	8,105	8,811	7,166	9,954	9,419	7,773	10,132	11,658	8,771	8,713	7,197	9,957	8,400	9,679
Cashflow From Investing	-101.4%	-9,254	657,172	-44,199	42,697	-20,327	-15,556	-18,989	1,680,120	-24,226	-6,277	-34,429	-30,771	-52,766	-44,109	-33,410	481,334	-212,803	129,294	-149,812	-206,161	-104,896
Cashflow From Financing	86.6%	-38,454	-285,954	-62,966	-133,546	-50,080	-67,726	-7,514	-1,190,025	-9,499	-23,678	113,443	16,970	7,743	52,146	-9,516	-402,371	176,841	-140,166	72,713	152,939	61,182
Buy Backs	-64.1%	33,659	93,693	49,679	108,490	-	308,953	-	279,581	45,568	-	9,714	9,300	37,090	-	65,070	37,023	-	44,306	57,599	-	-

MDRX Income Statement

2022-09-30

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Revenue from contract with customers	$ 151,922	$ 144,668	$ 445,492	$ 419,526
Cost of revenue:
Total cost of revenue	68,486	75,028	209,093	218,550
Gross profit	83,436	69,640	236,399	200,976
Selling, general and administrative expenses	32,518	27,392	133,683	87,680
Research and development	23,681	21,042	69,851	62,644
Asset impairment charges	0	359	0	531
Amortization of intangible and acquisition-related assets	2,236	2,363	6,648	7,090
Income from operations	25,001	18,484	26,217	43,031
Interest expense	(1,246)	(3,617)	(5,269)	(9,709)
Other income, net	1,655	4,493	3,800	21,819
Gain on sale of businesses, net	0	8,363	0	8,363
Equity in net loss income of unconsolidated investments	(617)	(257)	(1,222)	(321)
Income from continuing operations before income taxes	24,793	27,466	23,526	63,183
Income tax (provision) benefit	(13,868)	(7,190)	9,132	(12,464)
Income from continuing operations, net of tax	10,925	20,276	32,658	50,719
Income (loss) from discontinued operations	(434)	(6,187)	(9,252)	(6,545)
Gain on sale of discontinued operations	5,174	0	7,939	647
Income tax effect on discontinued operations	(1,137)	2,091	(57,986)	2,342
Income (loss) from discontinued operations, net of tax	3,603	(4,096)	(59,299)	(3,556)
Net income (loss)	$ 14,528	$ 16,180	$ (26,641)	$ 47,163
Basic
Continuing operations	$ 0.10	$ 0.16	$ 0.29	$ 0.38
Discontinued operations	0.03	(0.03)	(0.52)	(0.03)
Net earnings (loss) per Common Share	0.13	0.13	(0.23)	0.35
Diluted
Continuing operations	0.09	0.15	0.25	0.36
Discontinued operations	0.03	(0.03)	(0.44)	(0.03)
Net earnings (loss) per Common Share	$ 0.12	$ 0.12	$ (0.19)	$ 0.33
Provider [Member]
Revenue:
Revenue from contract with customers	$ 122,811	$ 118,179	$ 360,415	$ 345,253
Cost of revenue:
Total cost of revenue	57,252	61,606	172,595	180,566
Payer & Life Sciences [Member]
Revenue:
Revenue from contract with customers	29,111	26,489	85,077	74,273
Cost of revenue:
Total cost of revenue	$ 11,234	$ 13,422	$ 36,498	$ 37,984

MDRX Balance Sheet

2022-09-30

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 492,597	$ 132,517
Restricted cash	1,307	1,308
Accounts receivable, net of allowance of $12,868 and $13,360 as of September 30, 2022 and December 31, 2021, respectively	169,029	171,622
Contract assets, net of allowance of $564 and $576 as of September 30, 2022 and December 31, 2021, respectively	65,453	63,429
Prepaid expenses and other current assets	74,384	60,511
Assets held for sale	8,000	331,955
Total current assets attributable to discontinued operations	810,770	761,342
Fixed assets, net	11,713	9,819
Software development costs, net	78,103	74,688
Intangible assets, net	145,255	149,690
Goodwill	523,927	506,607
Deferred taxes, net	6	0
Contract assets - long-term, net of allowance of $1,201 and $1,534 as of September 30, 2022 and December 31, 2021, respectively	27,957	28,174
Right-of-use assets - operating leases	14,520	18,324
Other assets	78,408	83,429
Long-term assets attributable to discontinued operations	0	793,156
Total assets	1,690,659	2,425,229
Current liabilities:
Accounts payable	12,609	5,281
Accrued expenses	82,917	54,518
Accrued compensation and benefits	33,857	31,055
Deferred revenue	98,930	120,748
Current operating lease liabilities	6,166	6,133
Current liabilities attributable to discontinued operations	18,612	329,347
Total current liabilities attributable to discontinued operations	253,091	547,082
Long-term debt	200,326	350,062
Deferred revenue	3,060	1,839
Deferred taxes, net	8,082	16,625
Long-term operating lease liabilities	12,315	16,754
Other liabilities	36,762	33,823
Long-term liabilities attributable to discontinued operations	0	50,906
Total liabilities	513,636	1,017,091
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2022 and December 31, 2021; 279,600 and 109,260 shares issued and outstanding as of September 30, 2022, respectively; 276,705 and 116,114 shares issued and outstanding as of December 31, 2021, respectively	2,794	2,766
Treasury stock: at cost, 170,340 and 160,591 shares as of September 30, 2022 and December 31, 2021, respectively	(1,498,836)	(1,321,805)
Additional paid-in capital	1,923,559	1,962,386
Retained earnings	753,392	767,556
Accumulated other comprehensive loss	(3,886)	(2,765)
Total stockholders’ equity	1,177,023	1,408,138
Total liabilities and stockholders’ equity	$ 1,690,659	$ 2,425,229

About Allscripts Healthcare Solutions Inc

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

CEO	Mr. Richard J. Poulton
WEBSITE	https://veradigm.com
INDUSTRY	Healthcare Plans
EMPLOYEES	8000

Allscripts Healthcare Solutions Inc Frequently Asked Questions

What is the ticker symbol for Allscripts Healthcare Solutions Inc? What does MDRX stand for in stocks?

MDRX is the stock ticker symbol of Allscripts Healthcare Solutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allscripts Healthcare Solutions Inc (MDRX)?

As of Mon Apr 15 2024, market cap of Allscripts Healthcare Solutions Inc is 934.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDRX stock?

You can check MDRX's fair value in chart for subscribers.

What is the fair value of MDRX stock?

You can check MDRX's fair value in chart for subscribers. The fair value of Allscripts Healthcare Solutions Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allscripts Healthcare Solutions Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allscripts Healthcare Solutions Inc a good stock to buy?

The fair value guage provides a quick view whether MDRX is over valued or under valued. Whether Allscripts Healthcare Solutions Inc is cheap or expensive depends on the assumptions which impact Allscripts Healthcare Solutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDRX.

What is Allscripts Healthcare Solutions Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, MDRX's PE ratio (Price to Earnings) is 15.41 and Price to Sales (PS) ratio is 1.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Allscripts Healthcare Solutions Inc's stock?

In the past 10 years, Allscripts Healthcare Solutions Inc has provided -0.076 (multiply by 100 for percentage) rate of return.